Breaking the Rebate Model
The most consequential number in the FTC’s settlement is January 1, 2028, the latest date by which Express Scripts must comply with the new rules “as soon as commercially feasible.” That deadline sets the outer bound for transforming one of the U.S. drug channel’s largest intermediaries. Express Scripts, along with Evernorth Health, Medco Health Services, and Ascent Health Services, has accepted terms that effectively end the business model built on spread pricing, rebate-driven margins, and opaque formulary economics.
The FTC now requires that patients’ out-of-pocket costs be based on net price, not list price, which rewires the entire margin structure. PBM profitability has traditionally flowed from the gross-to-net spread: rebates and fees on high-WAC (wholesale acquisition cost) drugs padded PBM revenue while masking true costs to plans and members. Moving every patient exposure and plan calculation to the net level eliminates that spread. From here on, the only path to PBM revenue lies in administrative fees and transparent per-claim service pricing rather than rebate manipulation. A fairly radical reset.
Numbers That Reshape the PBM Channel
A key prohibition, no favoring high-WAC drugs over lower-cost equivalents, cuts straight into the economics of formulary design. Under the old model, higher-WAC drugs produced bigger rebate checks even when net cost didn’t justify their rank. The new rules break that link. Express Scripts now must make placement decisions on clinical merit or true net cost, flattening the competitive ground for drug makers and leaving less space for rebate economics to distort coverage.
Another pressure point is the mandated point-of-sale rebate pass-through. Every rebate has to reach the patient at the counter, not trickle back through plan accounting. Although the FTC order doesn’t state a specific percentage, the practical outcome is 100% of rebates flowing directly to members for all Express Scripts contracts under this order. This transforms rebate transparency from an abstract policy topic into something patients feel at the register.
The manufacturer fee delinking from list price rule dismantles yet another opaque mechanism. Previously, service fees tied to list price rewarded manufacturers for maintaining inflated list levels. Now those fees must be decoupled, flat-per-unit or value-based instead. The effect: narrower negotiation spreads and a necessary shift from leverage to operational efficiency as the core PBM competency. It’s less showmanship, more math.
The new cost-plus reimbursement formula for retail pharmacies adds a missing link in the chain. Rather than hide behind maximum allowable cost benchmarks, pharmacies will now receive acquisition cost plus a clearly defined markup. This echoes cost-plus cash models already visible among independent operators and pushes pricing back into daylight. While the markup itself isn’t published, the move dismantles hidden spreads and parallels broader transparency reforms in PBM pricing.
One more data point, the relocation of Ascent Health Services’ GPO from Switzerland to the United States, closes a structural gap. By pulling those rebate conduits under U.S. jurisdiction, the FTC gains direct oversight of contracting and audit trails. The message is plain: the old offshore rebate networks are done.
Compliance Timelines and Market Implications
The settlement introduces a formal compliance monitor with mandatory reporting requirements, ensuring this shift won’t be voluntary or cosmetic. It essentially establishes a multi-year, regulator-supervised rebuild of PBM operations. Public documentation and federal scrutiny will insert cost discipline where none existed before, and plenty of internal reporting teams are already redoing their models.
A curveball appears in the “Meeting Competition” clause (Section XI), which allows some flexibility if plan sponsors pressure Express Scripts to preserve rebate-like frameworks. That may temper early disruption if large employers or insurers cling to familiar discount optics. Yet unless that resistance becomes widespread, the settlement clearly anchors a transformation toward what Drug Channels has labeled the Net Pricing Drug Channel (NPDC), a system built on transparent, list-price-neutral economics rather than rebate choreography.
Speculation: The Next Competitive Repricing
If the order holds through 2028, the math suggests a compression of gross-to-net pools by several billion dollars across the PBM sector. Firms that relied on inflated list-price revenue will see margin pressure and must pivot to transactional or service-fee models. Manufacturers, finally freed from rebate distortions, can price closer to real cost without fearing lost formulary access. Employers and plan sponsors, armed with transparent data and cost-plus reimbursement, will overhaul benefit design around realized net costs. Expect more mergers among low-margin retail networks as those economics ripple through.
Competitors, OptumRx, CVS Caremark, and others, face a choice: adopt similar net models voluntarily or risk finding themselves the next subject of federal action. The FTC has redrawn the industry’s reference point. "Gross-to-net" now sounds like a relic. And honestly, maybe that’s overdue.
